Clinical TrialsADG126 in combination with pembrolizumab achieved an overall response rate of 22% and a disease control rate of 100% in nine evaluable patients without liver and peritoneal metastases.
Safety ProfileThe safety profile of ADG126 is differentiated, likely due to ADAG's proprietary SAFEbody technology, which allows antibodies to be selectively activated.
Stock ValuationThe ESMO update reinforces confidence in the ADG126’s potential in NLPM MSS-CRC, and the stock is considered undervalued.